NIAID
-
Study details RNA editing in virus-infected cancer cells
Vanderbilt researchers detail the landscape of RNA editing — a form of RNA modification — in primary effusion lymphoma cells during Kaposi’s sarcoma-associated herpesvirus infection and identify an edited viral microRNA that is critical for infection. Read MoreApril 20, 2023
-
Study identifies key player in T cell “education”
New Vanderbilt research could inform therapeutic strategies for enhancing thymic function when desired — such as during aging, recovery from radiation therapy or chemotherapy, or other conditions that reduce T cell output. Read MoreSeptember 1, 2022
-
Study describes how E. coli co-opts cells, causes recurrent UTIs
Researchers at Vanderbilt University Medical Center have discovered why the uropathogenic bacterium E. coli, the leading cause of urinary tract infections, is so tenacious; their findings could lead to new ways to prevent recurrent UTIs. Read MoreAugust 25, 2022
-
Study identifies first cellular “chaperone” for zinc, sheds light on worldwide public health problem of zinc deficiency
A team led by Vanderbilt researchers has described and characterized the first zinc metallochaperone: a protein that puts zinc into other “client” proteins. Read MoreMay 17, 2022
-
VUMC team discovers how bacterial pathogen survives without water
Vanderbilt researchers are studying a bacterial pathogen that can survive on hospital surfaces — without water — for months, an ability that has helped it become a leading cause of hospital-acquired infections. Read MoreMay 5, 2022
-
Study advances understanding of bacterial bioterrorism agent
Vanderbilt researchers have identified a critical regulatory factor in the bacterium that causes the disease anthrax and has been used as a biological weapon. Read MoreApril 7, 2022
-
Impaired neutrophils in autoimmunity
Vanderbilt researchers help answer the question of why patients with autoimmune diseases like lupus are more susceptible to bacterial infections: their neutrophils have impaired antibacterial activity. Read MoreJanuary 27, 2022
-
VUMC begins study of second COVID-19 vaccine
Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. Read MoreNovember 2, 2020
-
Risk marker for repeat sinus surgery
An inflammatory factor in mucus could be a biomarker of treatment-resistant chronic sinusitis used to determine which patients are at risk for repeat sinus surgery. Read MoreAugust 11, 2020
-
The importance of estrogen cycles
Deborah Lannigan and colleagues identify a key regulator of the estrogen receptor and suggest that its downregulation by oral contraceptives may increase oxidative stress and DNA damage, a common cause of cancer. Read MoreAugust 6, 2020